DF/HCC Program Affiliation

Breast Cancer

Research Abstract

Over the last decade my clinical and research interests have converged on breast cancer. I have been the Principal Investigator or Site Principal Investigator in a number of clinical trials which have led to the approval of new drugs (Herceptin, Xeloda) and to the testing of promising new compounds (new antiestrogens, selective estrogen receptor modulators, novel hematopoietic growth factors and retinoids), as well as interesting compounds which may have activity in breast cancer (somatostatin analogs). I have been involved in ongoing studies of a novel breast tumor marker and have been a major investigator in a trial studying predictors of response to neoadjuvant chemotherapy. I have a particular interest in hormone therapy of breast cancer and its biological basis, and am currently the International Coordinator for a multicenter trial studying predictors of response to neoadjuvant endocrine therapy using fulvestrant.

Publications

• Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM,.HER2 testing in breast cancer: NCCN Task Force report and re
  16813731
• Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN.Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophos
  16243442
• Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L, Halpern E, Moore R, Kuter I, Taghian A.Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer.AJR Am J Roentge
  15728611
• Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP.Preoperative therapy with trastuzumab and paclitaxel followed by sequ
  12506169
• Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing m
  11352965
• Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T.Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.J Clin Oncol 1999 Feb;17(2):485-93.
  10080589